Biogen Management

Management Kriterienprüfungen 4/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Chris Viehbacher

Geschäftsführender

US$4.1m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts39.3%
Amtszeit als Geschäftsführer2yrs
Eigentum des Geschäftsführers0.005%
Durchschnittliche Amtszeit des Managements4.5yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder4.4yrs

Jüngste Management Updates

Recent updates

Biogen Q3 Earnings Review: Why I Remain Optimistic Despite Difficult Quarter

Oct 31

Does Biogen (NASDAQ:BIIB) Have A Healthy Balance Sheet?

Oct 01
Does Biogen (NASDAQ:BIIB) Have A Healthy Balance Sheet?

What You Can Learn From Biogen Inc.'s (NASDAQ:BIIB) P/E

Sep 04
What You Can Learn From Biogen Inc.'s (NASDAQ:BIIB) P/E

Biogen: Q2 Earnings, Share Price May Have Bottomed Out As CEO Makes Mark

Aug 17

Biogen Stock: Cheapish, But With Few Growth Prospects

Jul 11

Is Biogen (NASDAQ:BIIB) Using Too Much Debt?

May 23
Is Biogen (NASDAQ:BIIB) Using Too Much Debt?

Biogen's Revenue Dip Meets Cost Cuts In Q1 (Rating Upgrade)

Apr 29

Earnings Update: Biogen Inc. (NASDAQ:BIIB) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

Apr 28
Earnings Update: Biogen Inc. (NASDAQ:BIIB) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

The Price Is Right For Biogen Inc. (NASDAQ:BIIB)

Apr 15
The Price Is Right For Biogen Inc. (NASDAQ:BIIB)

We Think You Can Look Beyond Biogen's (NASDAQ:BIIB) Lackluster Earnings

Feb 21
We Think You Can Look Beyond Biogen's (NASDAQ:BIIB) Lackluster Earnings

Biogen Inc. Just Missed EPS By 21%: Here's What Analysts Think Will Happen Next

Feb 16
Biogen Inc. Just Missed EPS By 21%: Here's What Analysts Think Will Happen Next

Biogen's Q4 Earnings Disappoint Amidst Strategic Challenges (Rating Downgrade)

Feb 14

Here's Why Biogen (NASDAQ:BIIB) Can Manage Its Debt Responsibly

Jan 31
Here's Why Biogen (NASDAQ:BIIB) Can Manage Its Debt Responsibly

Biotech And Pharma Diversification Pays Off

Jan 25

Getting In Cheap On Biogen Inc. (NASDAQ:BIIB) Might Be Difficult

Dec 26
Getting In Cheap On Biogen Inc. (NASDAQ:BIIB) Might Be Difficult

An Intrinsic Calculation For Biogen Inc. (NASDAQ:BIIB) Suggests It's 49% Undervalued

Oct 21
An Intrinsic Calculation For Biogen Inc. (NASDAQ:BIIB) Suggests It's 49% Undervalued

Is Biogen (NASDAQ:BIIB) Using Too Much Debt?

Oct 03
Is Biogen (NASDAQ:BIIB) Using Too Much Debt?

Is Biogen Inc. (NASDAQ:BIIB) Trading At A 31% Discount?

Jul 16
Is Biogen Inc. (NASDAQ:BIIB) Trading At A 31% Discount?

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Chris Viehbacher im Vergleich zu den Einnahmen von Biogen verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Sep 30 2024n/an/a

US$2b

Jun 30 2024n/an/a

US$1b

Mar 31 2024n/an/a

US$1b

Dec 31 2023US$4mUS$2m

US$1b

Sep 30 2023n/an/a

US$1b

Jun 30 2023n/an/a

US$3b

Mar 31 2023n/an/a

US$3b

Dec 31 2022US$30mUS$154k

US$3b

Vergütung im Vergleich zum Markt: ChrisDie Gesamtvergütung ($USD4.07M) liegt unter dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD12.74M).

Entschädigung vs. Einkommen: ChrisDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.


Geschäftsführer

Chris Viehbacher (63 yo)

2yrs

Amtszeit

US$4,069,913

Vergütung

Mr. Christopher A. Viehbacher, also known as Chris, is Director of Innocoll Holdings plc from July 24, 2017. He joined the Innocoll Holdings plc on July 24, 2017. He serves as President, Chief Executive Of...


Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Christopher Viehbacher
President2yrsUS$4.07m0.0048%
$ 1.1m
Michael McDonnell
Executive VP & CFO4.3yrsUS$7.17m0.013%
$ 3.0m
Nicole Murphy
Head of Pharmaceutical Operations & Technology2.8yrsUS$5.71m0.0066%
$ 1.5m
Susan Alexander
Executive VP & Chief Legal Officer18.8yrsUS$6.70m0.035%
$ 8.0m
Rachid Izzar
Head of Global Product Strategy & Commercialization3.8yrsUS$5.45m0.0067%
$ 1.5m
Robin Kramer
Senior VP & Chief Accounting Officer6yrskeine Daten0.0043%
$ 967.1k
Stephen Amato
Head of Investor Relationsless than a yearkeine Datenkeine Daten
Natacha Gassenbach
Chief Communication Officer & Head of Corporate Affairs4.8yrskeine Datenkeine Daten
Adam Keeney
Executive VP & Head of Corporate Development1.6yrskeine Daten0.00045%
$ 101.9k
Ginger Gregory
Executive VP & Chief Human Resources Officer7.3yrsUS$5.08m0.0093%
$ 2.1m
Alisha Alaimo
President & Head of North America7.3yrskeine Datenkeine Daten
Anabella Villalobos
Head of Biotherapeutics & Medicinal Sciences7.3yrskeine Datenkeine Daten

4.5yrs

Durchschnittliche Betriebszugehörigkeit

58yo

Durchschnittliches Alter

Erfahrenes Management: BIIBDas Führungsteam des Unternehmens gilt als erfahren (4.5 Jahre durchschnittliche Betriebszugehörigkeit).


Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Christopher Viehbacher
President2yrsUS$4.07m0.0048%
$ 1.1m
Stephen Sherwin
Independent Director14.7yrsUS$435.32k0.013%
$ 2.9m
William Hawkins
Independent Director5.4yrsUS$425.73k0.0044%
$ 1.0m
Caroline Dorsa
Independent Chair of the Board14.8yrsUS$646.13k0.017%
$ 3.9m
Eric Rowinsky
Independent Director14.7yrsUS$418.02k0.014%
$ 3.2m
Maria Freire
Independent Director3.4yrsUS$412.90k0.0031%
$ 690.8k
Lloyd Minor
Directorsless than a yearkeine Datenkeine Daten
Monish Patolawala
Independent Directorless than a yearkeine Daten0.00092%
$ 208.4k
Jesus Mantas
Independent Director5.4yrsUS$433.23k0.0051%
$ 1.1m
Susan Langer
Independent Director1.4yrsUS$334.53k0.0019%
$ 428.1k

4.4yrs

Durchschnittliche Betriebszugehörigkeit

65yo

Durchschnittliches Alter

Erfahrener Vorstand: BIIBDie Vorstandsmitglieder gelten als erfahren (4.4 Jahre durchschnittliche Amtszeit).